<DOC>
	<DOC>NCT00002002</DOC>
	<brief_summary>The primary objective of the study is to evaluate the effectiveness of l-leucovorin in preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS.</brief_summary>
	<brief_title>A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pneumonia, Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Inclusion Criteria Patients must have the following: Diagnosis of PCP. Fit the CDC definition of AIDS. Be receiving intravenous or oral trimethoprim / sulfamethoxazole (Bactrim, Septra) in doses of = or &gt; 15mg/kg/day of the trimethoprim component. Be receiving = or &lt; 48 hours of trimethoprim / sulfamethoxazole (TMP / SMX) prior to randomization. Must sign informed consent in accordance with FDA guidelines. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Cannot take oral medications. Require continued administration of anticonvulsant agents such as phenytoin, phenobarbital or primidone. Concurrent Medication: Excluded: Continued administration of anticonvulsant agents such as phenytoin, phenobarbital or primidone. Patients with the following are excluded: Cannot take oral medications. Require continued administration of anticonvulsant agents such as phenytoin, phenobarbital or primidone. Prior Medication: Excluded: &gt; 48 hours of trimethoprim / sulfamethoxazole prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1992</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia, Pneumocystis carinii</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>